Clorox (NYSE:CLX) Price Target Increased to $145.00 by Analysts at Wells Fargo & Co

Clorox (NYSE:CLX) had its price target hoisted by Wells Fargo & Co from $135.00 to $145.00 in a research report sent to investors on Wednesday, October 17th, The Fly reports. The firm currently has a market perform rating on the stock.

Other analysts have also issued research reports about the company. UBS Group began coverage on Clorox in a report on Wednesday, July 18th. They set a sell rating and a $110.00 target price for the company. BMO Capital Markets reiterated a buy rating and set a $153.00 price objective on shares of Clorox in a report on Friday, August 3rd. ValuEngine upgraded Clorox from a hold rating to a buy rating in a report on Saturday, September 22nd. Zacks Investment Research upgraded Clorox from a hold rating to a buy rating and set a $171.00 price objective for the company in a report on Wednesday, October 3rd. Finally, Deutsche Bank lowered Clorox from a hold rating to a sell rating and set a $123.00 price objective for the company. in a report on Wednesday, October 10th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $141.64.

Clorox stock traded up $1.03 during mid-day trading on Wednesday, reaching $158.77. 1,225,605 shares of the company were exchanged, compared to its average volume of 1,253,548. The company has a quick ratio of 0.65, a current ratio of 1.07 and a debt-to-equity ratio of 3.38. The firm has a market cap of $20.25 billion, a P/E ratio of 25.36, a P/E/G ratio of 3.89 and a beta of 0.28. Clorox has a 12-month low of $113.57 and a 12-month high of $159.17.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, October 31st. The company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.03. The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.53 billion. Clorox had a return on equity of 102.65% and a net margin of 13.59%. Clorox’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.46 earnings per share. Equities analysts expect that Clorox will post 6.31 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 16th. Investors of record on Wednesday, October 31st will be paid a $0.96 dividend. The ex-dividend date is Tuesday, October 30th. This represents a $3.84 dividend on an annualized basis and a yield of 2.42%. Clorox’s dividend payout ratio (DPR) is 61.34%.

In related news, SVP Michael R. Costello sold 9,265 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $140.02, for a total value of $1,297,285.30. Following the completion of the transaction, the senior vice president now owns 34,293 shares in the company, valued at approximately $4,801,705.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Diego J. Barral sold 12,880 shares of the firm’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $157.98, for a total value of $2,034,782.40. Following the completion of the transaction, the senior vice president now owns 18,603 shares of the company’s stock, valued at approximately $2,938,901.94. The disclosure for this sale can be found here. Insiders sold a total of 96,353 shares of company stock valued at $14,762,793 in the last 90 days. 1.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in CLX. Dimensional Fund Advisors LP grew its position in Clorox by 2.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 490,848 shares of the company’s stock worth $65,337,000 after purchasing an additional 10,505 shares during the period. Nuveen Asset Management LLC acquired a new stake in Clorox during the 1st quarter worth about $423,000. Allianz Asset Management GmbH grew its position in Clorox by 7.3% during the 1st quarter. Allianz Asset Management GmbH now owns 27,271 shares of the company’s stock worth $3,630,000 after purchasing an additional 1,848 shares during the period. The Manufacturers Life Insurance Company grew its position in Clorox by 8.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 160,442 shares of the company’s stock worth $21,357,000 after purchasing an additional 12,574 shares during the period. Finally, Millennium Management LLC grew its position in Clorox by 539.2% during the 1st quarter. Millennium Management LLC now owns 63,727 shares of the company’s stock worth $8,483,000 after purchasing an additional 53,757 shares during the period. 78.35% of the stock is currently owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

The Fly

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply